Source link : https://www.newshealth.biz/health-news/glp-1-benefits-risks-detailed-in-atlas-mapping-outcomes/
A study of more than two million people with diabetes builds on evidence of broad-ranging benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the clinical setting, providing an “atlas” mapping extensive outcomes and some new insights to potentially explore in more rigorous clinical trials. “This is the largest study on GLP-1 […]
Author : News Health
Publish date : 2025-01-23 09:54:49
Copyright for syndicated content belongs to the linked Source.